Zacks Research Research Analysts Raise Earnings Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Stock analysts at Zacks Research lifted their Q3 2024 earnings per share estimates for shares of Sarepta Therapeutics in a research note issued on Monday, April 29th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings of $0.50 per share for the quarter, up from their previous estimate of $0.49. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.13 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q4 2024 earnings at $0.84 EPS, Q1 2025 earnings at $0.58 EPS, Q2 2025 earnings at $1.09 EPS, Q3 2025 earnings at $1.57 EPS, Q4 2025 earnings at $2.07 EPS, FY2025 earnings at $5.30 EPS and Q1 2026 earnings at $1.73 EPS.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.50. The company had revenue of $396.80 million for the quarter, compared to the consensus estimate of $387.18 million. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The firm’s revenue was up 53.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.24) EPS.

SRPT has been the topic of a number of other reports. Evercore ISI upped their price target on Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an “in-line” rating in a research note on Tuesday, February 20th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $128.00 target price on shares of Sarepta Therapeutics in a report on Thursday, February 29th. UBS Group upped their target price on Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a report on Friday, March 1st. Wedbush reaffirmed an “outperform” rating and issued a $224.00 target price on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Finally, Royal Bank of Canada upped their target price on Sarepta Therapeutics from $151.00 to $157.00 and gave the company an “outperform” rating in a report on Thursday, February 29th. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $156.60.

Sarepta Therapeutics Stock Down 1.7 %

SRPT stock opened at $126.66 on Tuesday. The stock’s 50 day simple moving average is $125.99 and its 200 day simple moving average is $110.36. Sarepta Therapeutics has a fifty-two week low of $55.25 and a fifty-two week high of $159.89. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.45 and a current ratio of 3.95. The company has a market cap of $11.97 billion, a P/E ratio of -20.70 and a beta of 0.94.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $122.93, for a total transaction of $93,549.73. Following the sale, the director now owns 7,516 shares in the company, valued at $923,941.88. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, insider Bilal Arif sold 2,000 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the transaction, the insider now owns 26,836 shares of the company’s stock, valued at $3,457,550.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the transaction, the director now directly owns 7,516 shares in the company, valued at approximately $923,941.88. The disclosure for this sale can be found here. Insiders have sold a total of 22,096 shares of company stock worth $2,739,419 over the last 90 days. Corporate insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Handelsbanken Fonder AB grew its stake in shares of Sarepta Therapeutics by 14.5% during the third quarter. Handelsbanken Fonder AB now owns 15,915 shares of the biotechnology company’s stock valued at $1,929,000 after buying an additional 2,013 shares during the last quarter. Harbor Capital Advisors Inc. grew its stake in shares of Sarepta Therapeutics by 6.4% during the third quarter. Harbor Capital Advisors Inc. now owns 3,244 shares of the biotechnology company’s stock valued at $393,000 after buying an additional 196 shares during the last quarter. DMC Group LLC grew its stake in shares of Sarepta Therapeutics by 2.9% during the third quarter. DMC Group LLC now owns 3,297 shares of the biotechnology company’s stock valued at $400,000 after buying an additional 93 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Sarepta Therapeutics by 5.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 95,865 shares of the biotechnology company’s stock valued at $11,621,000 after buying an additional 4,763 shares during the last quarter. Finally, TD Asset Management Inc grew its stake in shares of Sarepta Therapeutics by 377.7% during the third quarter. TD Asset Management Inc now owns 204,626 shares of the biotechnology company’s stock valued at $24,805,000 after buying an additional 161,788 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.